Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Cash: 2014-2024

Historic Change in Cash for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to -$141.3 million.

  • Syndax Pharmaceuticals' Change in Cash fell 70.42% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.2 million, marking a year-over-year decrease of 142.14%. This contributed to the annual value of -$141.3 million for FY2024, which is 163.90% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Change in Cash of -$141.3 million as of FY2024, which was down 163.90% from $221.1 million recorded in FY2023.
  • Syndax Pharmaceuticals' Change in Cash's 5-year high stood at $221.1 million during FY2023, with a 5-year trough of -$147.6 million in FY2022.
  • Its 3-year average for Change in Cash is -$22.6 million, with a median of -$141.3 million in 2024.
  • Its Change in Cash has fluctuated over the past 5 years, first spiked by 1,078.66% in 2020, then crashed by 238.31% in 2022.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Change in Cash stood at $90.6 million in 2020, then rose by 17.75% to $106.7 million in 2021, then tumbled by 238.31% to -$147.6 million in 2022, then skyrocketed by 249.81% to $221.1 million in 2023, then crashed by 163.90% to -$141.3 million in 2024.